Korsana Biosciences 3Q 2026: EPS ($3.19) — 10-Q Summary
Korsana Biosciences reported a wider net loss of $46.43M in 3Q 2026, up 113.7% YoY, due to increased R&D and administrative expenses. EPS was ($3.19). The company plans regulatory filings for KRSA-028 and expects pharmacokinetic data in 2027. Cash reserves total $456.2M, expected to last into 2029.
How this was made
The 30-second read
Why it matters
The earnings miss and higher expenses suggest near‑term downside pressure, but the company retains $456.2M cash to fund operations into 2029.
Market read
Primary earnings disclosure for a micro‑cap biotech; new loss figures likely drive short‑term sell‑off.
What to watch
Potential upcoming IND filing in 2027 could offset short‑term pain if trial data is positive.
Background
Korsana Biosciences (KRSA) filed its Q3 2026 10‑Q, reporting a net loss of $46.43M and EPS of -$3.19, with increased R&D and SG&A expenses.
Ticker impact
10-Q filing shows Q3 net loss of $46.43M and EPS of -$3.19, wider than prior year.
likely pressure as the market prices in the widened loss
New earnings data reveals higher costs and a significant loss, which typically triggers sell‑offs in micro‑cap biotech stocks.
Market effects
Biotech sector may see modest pullback as investors reassess cash burn rates.
Limited to US biotech investors; no broader regional effect.
Minimal global impact; primarily relevant to KRSA shareholders.
Counterpoint
Some investors may view the cash runway to 2029 as a buying opportunity despite the loss.
Key entities
- companyKorsana Biosciences
US‑listed biotech firm reporting Q3 2026 results.
